<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2003</study_start_year><condition>Neoplasm Metastasis</condition><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Neoplasm Metastasis</disease><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2013775</full_dataset_link><location>United States</location><study_start_month>3</study_start_month><keyword>Erlotinib Hydrochloride</keyword><keyword>Metastatic Colorectal Cancer</keyword><keyword>Xeloda</keyword><keyword>Colorectal</keyword><keyword>Oxaliplatin</keyword><keyword>Tarceva</keyword><keyword>Capecitabine</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer</name><description>This trial is designed to investigate the safety, tolerability and the effectiveness when OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer.</description><dates><creation>2003-03-15</creation></dates><accession>2013775</accession><cross_references><ClinicalTrials___gov>NCT00123851</ClinicalTrials___gov></cross_references></HashMap>